February / March #68 : Sean's Trough Luck - by Lark Lands and Steven Miles, MD

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Archives » POZ Magazine issues




Table of Contents

A Daily Affirmation

Feed Your Head

TO: President George Bush

Puppet Masters

License to ddI

Longtime Companions: Tips For Two

You Sexy Thing

Indiana Jonesing

The Hanging CHAT

A Play In the Life

You Schmooze, You Lose

I Want My HIV

Speak Out

Once and Again

RetroPoz

Redemption Song

Art from the Heart

S.O.S: Mouth Off

Zen at Work

Three-Way

Lip-Locked

Suck It Up

Comfort Zone

His M.O. is Her N-0

Sean's Trough Luck

Soul Survivors

Dyke Strike

A Rage to Age

Blood Brothers

Mailbox

02.16.90 Radiant Baby

Milestones

Total Discord

Choosing Our Religion

Dogma & Devotion

The Brain Drain

Liver Lovers



Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV


email print

February / March 2001

Sean's Trough Luck

by Lark Lands and Steven Miles, MD

A new test of drug levels in the blood is a must-have to make the most of your regimen. Irish eyes have smiled on Sean's results. What about yours?

As told to Lark Lands

This month, Steven Miles, MD, associate professor of medicine at UCLA and director of the CARE Clinic at the university's AIDS Institute, reviews POZ Founder Sean Strub's protease drug-level test results and explains why too much or too little DIB (drug in blood) can cause treatment failure.


Other than brief upward blips immediately after his two drug holidays, Sean's viral load has remained undetectable with his combo of indinavir (Crixivan), d4T (Zerit) and delavirdine (Rescriptor). Wanting to keep it that way led his doctors to do a protease drug-level measurement (costs $60 to $80, usually reimbursed). The way that doctors understand how much of a protease inhibitor, or PI, actually stays in the bloodstream is by measuring the lowest concentration that the drug drops to just before the next dose -- the trough level. Drug levels are at their highest soon after each dose, then gradually decline. We measured Sean's trough level for Crixivan.

We don't do drug-level tests for nukes, like d4T, since they're activated after they get inside the cells, making blood measurements pointless. And non-nukes are used at such high levels that they're extremely effective, but the amounts used are unlikely to be toxic, so there's rarely a reason to measure them.

Unlike nukes and non-nukes, protease inhibitors (PIs) are generally poorly absorbed. People's ability to absorb and metabolize them also varies greatly. There may be only a small difference between an effective protease level and a toxic one, so taking the same dose, people can end up with very different blood levels. Low PI trough levels are associated with premature drug failure since at those low drug points the virus is not being sufficiently suppressed. Conversely, high trough concentrations cause needless toxicity. You need to dose just right: enough to inhibit the virus at all times but not so much that you cause avoidable side effects. A lot of the PI problems -- like dry skin, kidney stones or hair loss -- are largely due to excessive drug levels. Dropping the dose might maintain viral suppression but eliminate such symptoms.

At my practice, all new patients and patients who change PIs get a trough level at four weeks. We alter the dose based on results, and repeat the process every four weeks until the trough level is right. Measuring trough levels -- along with genotype (resistance testing), viral load and CD4s -- is also extremely important in determining why a patient's regimen is failing. In our experience, two-thirds of all patients fail protease inhibitors because of too little drug rather than viral resistance.

One way to ensure absorption is to boost PIs to a higher, more effective level to suppress the virus again. Adding ritonivir (Norvir) to saquinavir (Fort-ovase), amprenavir (Agenerase) or indinavir, for example, works well as a salvage therapy. However, toxicity is still a concern with this approach.

Sean did the test correctly, taking his previous dose as scheduled and then having blood drawn just before his next dose. His trough level was just right at 0.280 micrograms/per mililiter of blood. This helps explain why he has maintained undetectable viral load with few side effects. But for many others, doing PI drug levels and customizing doses based on the results could help prevent premature drug failure and reduce med toxicity.




[Go to top]

Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    guycmh328
    Columbus
    Ohio


    oceanblue65
    louisiana
    Louisiana


    max38man
    Chicago
    Illinois


    donnyp
    liberty
    Kentucky
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Survey
Pop Watch

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.